View Item 
        •   Utrecht University Student Theses Repository Home
        • UU Theses Repository
        • Theses
        • View Item
        •   Utrecht University Student Theses Repository Home
        • UU Theses Repository
        • Theses
        • View Item
        JavaScript is disabled for your browser. Some features of this site may not work without it.

        Browse

        All of UU Student Theses RepositoryBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

        The future of Benefit-Risk assessments of medicinal products

        Thumbnail
        View/Open
        12 06 22 Thesis MvB on B-R assessment - Final Version.doc (1.065Mb)
        Publication date
        2012
        Author
        Bruggen, M.H.C. van
        Metadata
        Show full item record
        Summary
        Introduction: Defining whether the benefit of a medicinal product outweighs its risk is a real challenge and needs to be assessed at several stages of the product life-cycle. Because the assessment is an important basis for decision-making for a broad group of stakeholders, it needs to be transparent and consistent. Furthermore, it is of interest to all stakeholders that the B-R assessment at the time of approval is predictive for the B-R profile of a marketed product. To increase predictability, the efficacy-effectiveness gap should be minimized. Methods: Based on a literature study and discussions with experts, main challenges with the current way in which B-R assessments of medicinal products are performed were identified. Furthermore, possible ways to address these main challenges were analyzed. The latter is also done by a literature study and by talking to experts. Results: Two main challenges with the current way of performing B-R assessments is the lack of transparency and consistency and the fact that the assessment at the time of approval is often not predictive for the B-R profile in a later stage. A more transparent and consistent way of performing B-R assessments can be achieved by using a descriptive/quantitative frameworks. Minimizing the efficacy-effectiveness gap can make the assessment of B-R at the time of approval more predictive for the B-R profile in a later stage. Conclusion: Current challenges with the way in which B-R assessments are performed will lead to significant changes in the near future. MAHs should adapt to this changing environment, by using developed frameworks for the assessment of B-R or by addressing potential ways to minimize the efficacy-effectiveness gap. Addressing the problem of poor-adherence and making use of biomarkers will help MAHs in getting their products on the market and maintaining this market approval by ensuring a safe and effective use.
        URI
        https://studenttheses.uu.nl/handle/20.500.12932/11875
        Collections
        • Theses
        Utrecht university logo